LYNX

Clinical Trial

NCT01265719 Completed

LYNX

Long-Term Non-Interventional Latanoprost Study

Observational

Disease

Disease type

Paediatric clinical trials

Orphan drug recognition

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

23/12/2010

Closing date

12/10/2017

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Others investigators

Pr Dr Markus Preising

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Dominique BREMOND-GIGNAC

Representative

France

Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Michael LARSEN

Representative

Denmark

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Dr Luca Buzzonetti

Representative

Italy

Anterior Segment Rare Eye Diseases (WG4)

Dr Yannick Lemer

Representative

France

Pr Martin Spitzer

Representative

Germany

Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Dr Johannes Birtel

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)